Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-03-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司、高盛（中国）证券有限责任公司关于百济神州有限公司与关联方共同投资暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure regarding a related party transaction involving BeiGene Ltd. and its investment in Pi Health Inc. It includes extensive information about the transaction background, parties involved, shareholding structure, pricing, rationale, and regulatory compliance. The document references regulatory rules from the Shanghai Stock Exchange and includes opinions from joint sponsors (investment banks). It is not a financial report like an annual or interim report, nor is it a simple announcement or voting result. It is a regulatory disclosure focused on a related party transaction and investment structure, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update (CAP) or M&A Activity (TAR) since it is about a related party investment and compliance review rather than a merger or financing announcement. The document length and detail confirm it is not a brief announcement or a certification letter, so RNS is appropriate as a comprehensive regulatory disclosure.
2024-03-05 Chinese
百济神州有限公司关于与关联方共同投资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from BeiGene Limited regarding the progress of a related party transaction involving investment and property acquisition. It details the transaction overview, parties involved, transaction price, payment terms, and risk warnings. The document is relatively short (1515 characters) and focuses on a specific transaction update rather than comprehensive financial data or report. It does not contain financial statements, earnings data, or management discussion typical of financial reports. It is not a report publication announcement since it provides substantive transaction details. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through investment and asset acquisition.
2024-03-05 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands, and listed on the Hong Kong Stock Exchange and Shanghai Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance, share option exercises, and share counts before and after changes, along with explanatory notes and confirmations by the company's executive director and CEO. The document length is 3993 characters, which is relatively short but contains substantive data on share capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-03-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It details share issuance under a share award plan, including the number of shares issued, dates, prices, and percentage changes in issued shares. The document also includes confirmations that the share issuance was duly authorized and complies with relevant listing rules. The content is focused on share capital changes and disclosures thereof, not on financial results, management changes, or other report types. The document length is about 5,159 characters, which is sufficient to contain substantive data rather than just an announcement. Therefore, this fits the category of Share Issue/Capital Change (SHA).
2024-02-29 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company, referencing specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It includes data on share issuance under equity incentive plans, share counts before and after issuance, prices, and related notes. The document is not a general financial report, earnings release, or management discussion, but a regulatory disclosure specifically about share capital changes. This matches the definition of a Share Issue/Capital Change announcement (SHA). The document length is over 5,000 characters and contains substantive data, so it is not merely an announcement of a report publication or a regulatory filing. Therefore, the correct classification is SHA with high confidence.
2024-02-27 Chinese
百济神州有限公司自愿披露关于百泽安（替雷利珠单抗注射液）获欧洲药品管理局人用药品委员会积极意见的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 百济神州有限公司 regarding the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion on the drug 百泽安 (替雷利珠单抗注射液) for marketing authorization. It details clinical trial results, drug indications, and potential impacts on the company. The document is an announcement of regulatory progress and risk factors related to the drug approval process. It does not contain financial statements, earnings data, or detailed management discussion of financial results. The document length is 3682 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full annual report, interim report, earnings release, or other financial filing. It is a regulatory announcement about a drug approval status and associated risks. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-02-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.